PSC

Global Market for Augmented Reality (AR) in Training & Education to Cross $68.7 Billion by 2026 - AR Game-based Learning is Driving Industry Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 13, 2022
Entertainment, Education, Technology, Other Technology, Electronic Games, Training, Cortex, Knowledge, Technology, Learning, Augmented reality, Student, Reading, Education, Zspace, Demography, Meta (company), School, AR, PSC, GDP, Heart, COVID-19, Magic Leap, Geography, CAGR, Forecasting, Growth, Adoption, Curriculum, Google, Video game, Video game console, Tutoring, Retail, Augment

Technology is changing education in many ways but this newer advanced technology of augmented reality (AR) is improving the learning environment.

Key Points: 
  • Technology is changing education in many ways but this newer advanced technology of augmented reality (AR) is improving the learning environment.
  • Augmented reality game-based learning is the latest trend in the augmented reality in the training and education market.
  • Ineffective classroom integration is slowing down the growth of augmented reality in the training and education market.
  • It compares the augmented reality in training and education market with other segments of the augmented reality in training and education market by size and growth, historic and forecast.

Pliant Therapeutics Announces Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis

Retrieved on: 
Sunday, July 10, 2022
Cirrhosis, NASH, Patient, European Medicines Agency, Fatty liver disease, Pulmonary fibrosis, GLOBE, COVID-19, Food, YouTube, Serum, Vital capacity, Integrin, Fibrosis, Webcast, Conversation, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, FDA, QLF, HRCT, Analysis, Telephone, Muscular dystrophy, Pharmacokinetics, SAN, Event, Primary sclerosing cholangitis, Financial condition report, SEC, Risk, Result, Twitter, LinkedIn, IPF, PIN, Walking, Idiopathic pulmonary fibrosis, Partnership, Investor, Private Securities Litigation Reform Act, Nasdaq, News, Death, Annual report, HIV disease progression rates, Biomarker, SAE, Plasma, Population, FVC, PSC, Standard of care, Facebook, Safety, Interest, Program, Pharmaceutical industry, Medical imaging, Online shopping, Company, Novartis

SOUTH SAN FRANCISCO, Calif., July 10, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced positive data from INTEGRIS-IPF, a multinational, randomized, double-blind, placebo-controlled Phase 2a clinical trial of PLN-74809 in patients with idiopathic pulmonary fibrosis (IPF). The trial met its primary and secondary endpoints demonstrating that PLN-74809 was well tolerated over a 12-week treatment period and displayed a favorable pharmacokinetic profile. The trial’s exploratory efficacy endpoints assessing changes in forced vital capacity (FVC) and Quantitative Lung Fibrosis (QLF) imaging, demonstrated a dose-dependent treatment effect on FVC and QLF versus placebo over 12 weeks in PLN-74809 treated patients.

Key Points: 
  • ET
    SOUTH SAN FRANCISCO, Calif., July 10, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced positive data from INTEGRIS-IPF, a multinational, randomized, double-blind, placebo-controlled Phase 2a clinical trial of PLN-74809 in patients with idiopathic pulmonary fibrosis (IPF).
  • The primary endpoint of the INTEGRIS-IPF trial is the evaluation of the safety and tolerability of PLN-74809.
  • Of the 67 patients treated with PLN-74809, 65 (97%) completed 12 weeks of treatment with no discontinuations due to adverse events.
  • Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis.

Perspectum Announces American Medical Association (AMA) Issues Two Unique Category III CPT® Codes Priced Appropriately by the Centers for Medicare & Medicaid Services (CMS) for Noninvasive Biliary Anatomy Assessment With MRCP+

Retrieved on: 
Tuesday, July 5, 2022
Health Technology, Health, Medical Devices, Centers for Medicare & Medicaid Services, Diagnosis, MRCP, Biliary disease, Patient, American Medical Association, Precision medicine, European Association for the Study of the Liver, CMS, AMA, Anatomy, Center, EASL, Internal medicine, Cancer, Primary biliary cholangitis, AGAF, Association, Gallbladder, Cholestasis, Category, Liver disease, PSC, CPT, FACP, ERCP, Primary sclerosing cholangitis, Magnetic resonance cholangiopancreatography, Health, Pediatrics, Pancreatic duct, Genetics, Medicare, Physician, MD, MRI, Baylor College of Medicine, Hospital, Medical imaging, Medicaid, Liver

Effective July 1, 2022, the Centers for Medicare & Medicaid Services (CMS) has issued appropriate reimbursement for the MRCP+ procedure.

Key Points: 
  • Effective July 1, 2022, the Centers for Medicare & Medicaid Services (CMS) has issued appropriate reimbursement for the MRCP+ procedure.
  • CPT 0723T has been assigned to APC 1511 New Technology Level 11, reimbursement range $900-$1000, effective July 1, 2022.
  • MRCP+ is an image analysis tool that enhances MRCP data to provide visualization and quantitative assessment of the biliary system.
  • The guidelines reference MRCP+ as a novel technique to automatically segment biliary anatomy and provide quantitative biliary tree metrics.

West Virginia American Water Files 2023 Infrastructure Replacement Plan and Distribution System Improvement Charge

Retrieved on: 
Thursday, June 30, 2022
Energy, Natural Resources, Utilities, Other Natural Resources, Water, Acquisition, LinkedIn, Public Service Commission, American Water Works, Maryland Public Service Commission, Map, History, American Water, PSC, Investment, NYSE, Facebook, Twitter, Program, Water distribution system, Renewable energy, American

West Virginia American Water filed an application today with the Public Service Commission (PSC) of West Virginia, seeking approval of its 2023 infrastructure replacement program and associated Distribution System Improvement Charge (DSIC).

Key Points: 
  • West Virginia American Water filed an application today with the Public Service Commission (PSC) of West Virginia, seeking approval of its 2023 infrastructure replacement program and associated Distribution System Improvement Charge (DSIC).
  • This infrastructure replacement plan and surcharge is reviewed and updated annually by the PSC, and the proposed 2023 rate includes approximately $81.2 million of investment for infrastructure replacement and system upgrades.
  • West Virginia American Waters annual infrastructure replacement program has been in place since 2017, and it gives us the ability to make timely, necessary investments in our water systems, said Robert Burton, president of West Virginia American Water.
  • West Virginia American Water, a subsidiary of American Water (NYSE: AWK), is the largest investor-owned water utility in the state, providing high-quality and reliable water services to approximately 560,000 people.

Chemomab Awarded New U.S. Patent for CM-101, Its First-in-Class CCL24 Neutralizing Antibody

Retrieved on: 
Tuesday, June 28, 2022
TEL, Cirrhosis, Liver, Patient, CMMB, Antibody, Treatment, Research, Method, Marketing, PK, Inflammation, Therapy, CCL24, PSC, Composition, Private Securities Litigation Reform Act, Bile, Communication, Primary sclerosing cholangitis, Doctor of Philosophy, Fibrosis, SEC, Risk, Use, Drug, Patent, Fatty liver disease, Nature, Forward-looking statement, Institute of Liver and Biliary Sciences, Pharmaceutical industry, Vaccine

TEL AVIV, Israel, June 28, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today reported that the United States Patent and Trademark Office has issued a new patent for CM-101, Chemomab's first-in-class monoclonal antibody that neutralizes CCL24, a novel disease target at the confluence of fibrosis and inflammation. The new patent covers the use of CM-101 and sequence-related CCL24 antibodies for the treatment of hepatic (liver) diseases. CM-101 is currently in a Phase 2 trial for the treatment of primary sclerosing cholangitis (PSC), a potentially lethal disease affecting the bile ducts of the liver, as well as a Phase 2 liver fibrosis study.

Key Points: 
  • The new patent covers the use of CM-101 and sequence-related CCL24 antibodies for the treatment of hepatic (liver) diseases.
  • "We have been diligent in obtaining expanded intellectual property coverage for CM-101 and sequence-related CCL24 neutralizing antibodies," noted Adi Mor, PhD, co-founder and Chief Scientific Officer of Chemomab.
  • CM-101 is a monoclonal antibody that neutralizes the soluble protein CCL24, a cytokine family member that can trigger self-reinforcing inflammatory and fibrotic pathways implicated in a number of serious progressive diseases.
  • Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity.

Biliary Tract Cancers (BTCs) Market Research Report 2019-2032 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 28, 2022
Health, Oncology, Diagnosis, PCCA, Acquisition, Biliary tract, Systematic review, Patient, Biopsy, Cisplatin, Epidemiology, Comprehension, Lists of people executed in the United States, Orange Riots, Fluorescence, Primary sclerosing cholangitis, Meta-analysis, CCA, PS 2, PET-CT, Gemcitabine, CT, Oxaliplatin, ESMO, Risk, SME, Therapy, PSC, Serum, Radiation, Cholestasis, Technology, ICCA, BTC, Ultrasound, Chromoendoscopy, Chemoradiotherapy, PS, News, MRI, Table, Gaps, Dietary supplement, Medical imaging, Pharmaceutical industry, Phase II, Cholangiocarcinoma

The "Biliary Tract Cancers (BTCs) - Market Insight, Epidemiology And Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biliary Tract Cancers (BTCs) - Market Insight, Epidemiology And Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
  • The Biliary Tract Cancer market report provides current treatment practices, emerging drugs, Biliary Tract Cancer market share of the individual therapies, current and forecasted Biliary Tract Cancer market Size from 2019 to 2032 segmented by seven major markets.
  • The report also covers current Biliary Tract Cancer treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
  • The Biliary Tract Cancer market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Biliary Tract Cancer market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers and demand of better technology.

Georgia Power requests funding to support essential, critical investments in electric grid reliability, cleaner and more economical energy resources and better customer experience

Retrieved on: 
Friday, June 24, 2022
Nuclear Regulatory Commission, New York City Administration for Children's Services, Annual report, The Salvation Army, Transport, CEO, Ownership, Carbon, Wind, Coal, Investment, File, Family, Energy certificate, Tornado, Public expenditure, Growth, Division, Industry, IRP, Flood, Georgia Public Service Commission, Pacific typhoon season, Fire, GIP, Earthquake, EV, Prepayment, Partnership, PSC, Stewardship, Retirement, Technology, Customer service, NYSE, Natural gas, LIHEAP, Solution, J.D. Power, Temperature, Explosion, Heat, Drought, Program, Multimedia, Income, Electricity, CIS, Renewable energy, Electric power industry, Public utility, Health insurance, Online shopping, Tutoring, Southern Company, Georgia Power, Facebook, Instagram, Twitter

ATLANTA, June 24, 2022 /PRNewswire/ -- Georgia Power today filed a request with the Georgia Public Service Commission (PSC) that would enable the company to continue making investments in strengthening and further securing the electric grid, transforming its power generation to include cleaner and more economical energy resources and continue improving the customer experience. 

Key Points: 
  • Enhancing operations and improving customer experience through investments in technology that will help enable Georgia Power to continue delivering exceptional service to customers while meeting their evolving energy needs.
  • Georgia Power is continuously investing in the power grid to make it smarter and more reliable, and today's filing looks to continue those efforts.
  • To support the transition, Georgia Power will continue serving customers with a diverse, balanced generation fleet of reliable, resilient and economical resources, which includes adding cost-effective renewable resources.
  • * REC Disclaimer: Georgia Power purchases only the null energy output from some renewable generating facilities that have contracted to sell that energy to Georgia Power.

Pliant Therapeutics Presents Preclinical Data Highlighting A Novel Approach for the Treatment of Muscular Dystrophies

Retrieved on: 
Wednesday, June 22, 2022
Fibrosis, PSC, FDA, Senior, Result, Risk, COVID-19, Cirrhosis, Annual report, Regeneration, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Duchenne muscular dystrophy, Integrin, Research, European Medicines Agency, Financial condition report, Private Securities Litigation Reform Act, LinkedIn, Disease, Investigational New Drug, Conversation, YouTube, Failure rate, Program, IND, Analysis, News, SEC, New Directions, Nasdaq, Primary sclerosing cholangitis, Partnership, Muscular dystrophy, Death, NASH, IPF, Twitter, Food, Patient, Facebook, DMD, Fatty liver disease, Idiopathic pulmonary fibrosis, Conference, Muscle, SAN, Therapy, GLOBE, Mouse, Pharmaceutical industry, Biology, Novartis

SOUTH SAN FRANCISCO, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) presented new preclinical data highlighting the potential of PLN-101325, an α7β1 integrin activating antibody​ for the treatment of muscular dystrophies, including Duchenne Muscular Dystrophy (DMD). These data were presented at the New Directions in Biology and Disease of Skeletal Muscle Conference being held June 20‐23, 2022 in Fort Lauderdale, Florida.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) presented new preclinical data highlighting the potential of PLN-101325, an 71 integrin activating antibody for the treatment of muscular dystrophies, including Duchenne Muscular Dystrophy (DMD).
  • It highlighted in vitro and in vivo data demonstrating improved cell morphology, tissue organization and muscle function in human cells and D2-MDX mice after treatment with PLN-101325.
  • Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis.
  • In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies.

Proactive news headlines including White Rock Minerals, Arovella Therapeutics, Critical Resources and Alice Queen

Retrieved on: 
Wednesday, June 22, 2022
Lithium, Elixir, MVL, Well, Ethereum, Hudson Institute of Medical Research, CRR, MRE, PSC, Gold, Antonio, CBM, Ludwig Quidde, OTCQX, OTCQB, Yilgarn Craton, Copper, Tower, GLOBE, Therapy, The Side, ASX, REE, Insomnia, AAU, Mineral resource estimation, AOI, Hyperion, Proactivity, Ironbark, Silver, Anomaly, SPP, White Rock, WRM, ORN, Zinc, EXR, Non-fungible token, MEK, KTA, JSE, AVL, BRK, NOX, Program, Medical research, LSE, CCZ, Mining, Rare-earth element, Oil, The Onedin Line

Click here

Key Points: 
  • Click here
    Arovella Therapeutics Ltd (ASX:ALA) welcomes STADA Australias commercial launch of ZolpiMist (zolpidem tartrate), a product indicated for the short-term treatment of insomnia in adults.
  • Click here
    Meeka Gold Ltd (ASX:MEK) has hit upon pervasive high-value, high-grade rare earths in assays from recent drilling at Circle Valley.
  • Proactive has produced over 300,000 articles and 20,000 executive interviews since it was established in 2006.
  • For more information on how Proactive can help you make a difference, email us at [email protected]

ExCellThera announces submission of Drug Master File for UM171

Retrieved on: 
Friday, June 17, 2022
Solution, Degenerative disease, Type, FDA, Regenerative medicine, B cell, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Lymphatic system, LSD1, Research, New Drug Application, Protein, GLOBE, Potency (pharmacology), DMF, Rejuvenation, Stem cell, Adult, Food, PSC, Patient, Food and Drug Administration, Astellas Institute for Regenerative Medicine, Pharmaceutical industry, IND

UM171 is a small molecule that leads to specific epigenetic modifications which have a profound impact on hematopoietic stem cell self-renewal.

Key Points: 
  • UM171 is a small molecule that leads to specific epigenetic modifications which have a profound impact on hematopoietic stem cell self-renewal.
  • UM171 has been cited in several scientific publications, and its mechanism of action was published in 2021 in the peer-reviewed journal, Cell Stem Cell.
  • ExCellThera has developed pre-formulated commercial-grade UM171 single-use vials that can be integrated into the manufacturing process of various cell and gene therapy products as a reagent.
  • A Drug Master File (DMF) is a submission to the Food and Drug Administration (FDA) that may be used to provide confidential detailed information about facilities, processes or materials used in the manufacturing, processing, packaging, and storing of human drugs and biologics.